Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sensimed AG
With
University Hospital, Geneva
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Older than 18 years.
Untreated IOP of ≥22 mmHg in both eyes.
Documented, typical glaucomatous visual field (VF) loss (nasal step, or arcuate, paracentral or Seidel's scotoma) determined by automated static threshold perimetry (Octopus 100), and glaucomatous optic nerve head cupping (neural rim notching or saucerization) in both eyes.
Patients under tafluprost treatment since at least 4 weeks in both eyes.
Patients who accept signing an informed consent approved by the Ethics Committee.
You may not be if
Patients not able to understand the nature of the research
Patients under tutorship
Corneal abnormalities in both eyes
Subjects with contraindications for wearing contact lenses
History of ocular surgery within the last 3 months
Known hypersensitivity to tafluprost or to any of its excipients
Full-frame metal glasses during monitoring with SENSIMED Triggerfish®
Pregnancy and lactation
Simultaneous participation in other clinical research
Patients with evidence of ocular infection or inflammation
Clareo Health | Use of an Ocular Telemetry Sensor in Tafluprost Treated Patients
